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Introduction
Invasive breast cancer is a heterogenous disease, with the majority of  tumors diagnosed as either invasive 
ductal carcinoma (IDC; ~80%) or invasive lobular carcinoma (ILC; ~8–14%). Pleomorphic ILC (PILC) 
is a relatively recent, formally recognized variant of  invasive lobular breast cancer that represents approx-
imately 10% of  lobular tumors (1). PILC shares histologic and molecular hallmarks with classic ILC 
(CILC), particularly its distinctive infiltrative growth pattern, lack of  E-cadherin expression, and common 
chromosomal alterations (1–3). However, PILC differs from CILC in its greater degree of  cellular atypia 
and nuclear pleomorphism, which is more similar to high-grade IDC. Molecular prognostic features of  
PILC also distinguish this lesion from CILC. Specifically, PILC tends to be ER/PR negative and HER2 
positive more frequently than CILC (3, 4).
PILC typically presents at advanced stages and is associated with larger tumor size, greater presence 
of  lymphovascular invasion, more frequent regional axillary lymph node involvement, and a higher rate 
of  distant metastasis when compared with CILC (1). These poor prognostic factors translate into reduced 
clinical outcomes with short relapse times, a higher risk of  recurrence, and decreased overall survival (5). 
A tendency toward lower complete response rates of  ILC to adjuvant chemotherapy has been observed 
when compared with IDC (4). However, given the relatively recent clinical recognition of  PILC, response 
data from independent studies on PILC are lacking. A greater understanding of  PILC biology is needed to 
explain its more aggressive behavior and to determine optimal clinical management.
The aim of  this study was to establish a molecular profile of  pleomorphic lobular carcinoma that 
could inform the mechanistic basis of  this breast cancer variant. Our data identify gain-of-function IRS2 
mutations that reveal a role for the insulin/IGF-1 signaling pathway in PILC and its potential to facilitate 
the invasive nature of  these tumors.
Results
Identification of  recurrently mutated genes in PILC. PILC tumors (Figure 1, A and B) and their paired normal 
tissues were subjected to targeted exome sequencing across the protein-coding exons and flanking splice 
sites of  the Beijing Genomics Institute TumorCare gene panel. The clinicopathological features of  the 
data set are presented in Table 1. The TumorCare gene panel includes 1,053 genes that were selected based 
upon previous reports of  being clinically actionable cancer genes, harboring high frequency alterations in 
the Catalog of  Somatic Mutations in Cancer (COSMIC) database (6), or playing a key role in pathways 
Pleomorphic invasive lobular carcinoma (PILC) is an aggressive variant of invasive lobular breast 
cancer that is associated with poor clinical outcomes. Limited molecular data are available to 
explain the mechanistic basis for PILC behavior. To address this issue, targeted sequencing was 
performed to identify molecular alterations that define PILC. This sequencing analysis identified 
genes that distinguish PILC from classic ILC and invasive ductal carcinoma by the incidence of their 
genomic changes. In particular, insulin receptor substrate 2 (IRS2) is recurrently mutated in PILC, 
and pathway analysis reveals a role for the insulin receptor (IR)/insulin-like growth factor-1 receptor 
(IGF1R)/IRS2 signaling pathway in PILC. IRS2 mutations identified in PILC enhance invasion, 
revealing a role for this signaling adaptor in the aggressive nature of PILC.
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associated with cancer (Supplemental Table 1; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.97398DS1). Total somatic muta-
tion events and copy number variations (CNVs) for each sample are shown in Figure 
1, D and E, respectively. There was no strong positive correlation between the total 
number of  molecular alterations in each sample and the depth of  coverage (Figure 1F). 
The somatic mutations and CNVs that occurred in PILC are provided in Supplemental 
Tables 2 and 3, respectively.
To identify genes that are functionally important for PILC, a filtered data set of  
molecular alterations that met specific criteria was established that included (a) all non-
sense, indel, and splice-site mutations; (b) copy number gains and losses; (c) missense 
mutations present in the COSMIC v77 database; and (d) novel missense mutations not 
present in COSMIC that were predicted to have protein-altering functional consequenc-
es by comprehensive computational prediction tools (Supplemental Table 4). Based 
upon these criteria, a total of  798 functional somatic mutation events were identified 
in 426 genes, with an average of  46.9 protein-altering mutations (range of  9–137) per 
sample (Figure 1G). Genes that were recurrently mutated in PILC (≥4 samples) are 
shown in Figure 1H.
IDC and ILC have distinct histological characteristics and clinical outcomes, and 
molecular alterations that distinguish these breast cancer variants have been identified 
(7–9). Comparison of  our data with published comprehensive genomic studies of  ILC 
and IDC revealed that PILC and ILC share many of  the significant alterations that 
are associated with ILC and confirmed molecular differences that distinguish ILC 
from IDC (7–9) (Figure 2, A and B, and Supplemental Table 5). PIK3CA, the catalytic 
subunit of  PI3K (10), was mutated at a high frequency (Figure 1H), with known gain-
of-function missense mutations in 9 of  17 (53%) of  the PILC samples (Figure 2C). 
Loss of  E-cadherin expression is a defining hallmark of  lobular neoplasias (2), and 
negative E-cadherin staining was confirmed for all PILC samples (Figure 1C). CDH1, 
which encodes for E-cadherin, was altered in 10 of  17 (59%) of  the PILC samples 
(Figure 1H), a mutation frequency similar to that reported previously for ILC (Figure 
2B and Supplemental Table 5) (7–9). All of  the CDH1 mutations were either frame-
shift indels or nonsense mutations that would be predicted to result in loss of  protein 
expression (Figure 2C). Additional genes with similar mutation frequencies in PILC 
and ILC, and that distinguish ILC from IDC, include TP53, RUNX1, GATA3, TBX3, 
and MYC (Figure 2, A and B).
Molecular alterations that distinguish PILC from ILC were identified in our study 
(Figure 2B). Amplification or mutation of  both HER2 (also known as ERBB2) and HER3 
(also known as ERBB3) occurred more frequently in PILC than in ILC (Figure 2B and 
Supplemental Table 5). Several additional genes were mutated at a markedly higher 
frequency in our PILC cohort when compared with ILC, and they represent PILC-asso-
ciated molecular alterations. These genes include KMT2C, MAP3K1, IRS2, NCOR1, NF1, and TBX3 (Fig-
ure 2B). The incidence of  PTEN molecular alterations may also distinguish PILC from ILC. Although the 
frequency of  PTEN mutations reported for ILC varies among published studies (1.4%–13%) (Supplemental 
Table 5), molecular alterations were not identified in either our study or a previous whole-exome sequenc-
ing (WES) analysis of  8 PILC tumors (11). In support of  a selective association of  PTEN loss with CILC, 
mice with combined loss of  Cdh1 and Pten develop mammary tumors that model human CILC (12). Of  
the recurrently mutated genes identified in our study, only TP53, CDH1, and PI3KCA were reported in the 
previous PILC WES (Supplemental Table 5) (11). The mutation detection differences in our studies likely 
reflect both the greater depth of  coverage provided by our targeted sequencing and the higher tumor con-
tent of  our samples (>60% vs. 30%).
The IRS2 signaling pathway is associated with PILC. To identify genes and pathways that drive the more 
aggressive nature of  PILC tumors, we analyzed our somatic mutation data using MUtations For Functional 
Impact on Network Neighbors (MUFFINN) (13). This program integrates mutational data for individual 
genes and their network neighbors to predict functional impact. Of  relevance for our study, MUFFINN 
shows high sensitivity for small sample sizes. We analyzed our data using the direct-neighbor max approach 
Table 1. Clinical characteristics of study cases
Characteristics No. (%, n = 16)A
Age at diagnosis, yr
Mean ± SD 67.5 ± 13.1
≥60 13 (81.3)
<60  3 (18.7)
Tumor size, cm
Mean ± SD 2.5 ± 1.5
≥2 8 (50)
<2 8 (50)
Tumor stage
0 0 (0)
I 5 (31.3)
II 10 (62.5)
III 1 (6.2)
Lymph node status
Positive 6 (37.5)
Negative 10 (62.5)
Hormone receptor status
BER positive 13 (81.3)
CPR positive 10 (62.5)
HER2 status
Positive 4 (25)
Negative 11 (68.8)
DEquivocal 1 (6.2)
Treatment
Lumpectomy 4 (25)
Mastectomy 11 (68.8)
Adjuvant radiation 8 (50)
Adjuvant chemotherapy 7 (43.7)
Adjuvant endocrine 
therapy
10 (62.5)
Anastrozole 7 (43.7)
Tamoxifen 3 (18.7)
AValues are shown, with percentages provided 
parenthetically, except when values are shown 
as mean ± SD. BER, estrogen receptor; CPR, 
progesterone receptor; HER2, human epidermal 
growth factor receptor 2. DBy IHC and FISH.
3insight.jci.org   https://doi.org/10.1172/jci.insight.97398
R E S E A R C H  A R T I C L E
with the HumanNet gene network (13). Prediction scores generated by this analysis range from 0 to 1, with 
a larger value indicating higher significance. Scores are indicated in the left column of  the Oncoprint plot in 
Figure 1H, and the top 10 genes predicted to contribute to PILC are shown in Table 2. PIK3CA and CDH1, 
genes known to play an important role in breast cancer and ILC, respectively, were assigned the highest pre-
dictive scores. IRS2 was ranked third, with genes encoding its upstream receptors insulin-like growth factor-1 
receptor (IGF1R) and IR (encoded by INSR), also ranked within the top 10 genes (Figure 2C). Network 
analysis for IRS2 revealed additional molecular alterations in both upstream regulators and downstream 
effectors of  IRS2 that support a role for this signaling adaptor in PILC (Figure 2D).
Figure 1. Molecular profile of pleomorphic invasive lobular carcinoma. (A and B) Representative images of H&E-stained pleomorphic invasive lobular 
carcinoma (PILC). (C) Representative image of E-cadherin staining in PILC. (D) Total mutation events across the PILC tumors (n = 17). (E) Distribution of copy 
number variant types (log2 ratio ≥1 or ≤–1) across the PILC tumors. (F) Mean coverage of sequenced PILC tumors and their matched normal controls. (G) Fil-
tered functional somatic alteration events identified in the PILC tumors. (H) Oncoprint heatmaps of recurrently altered genes in PILC. MUtations For Func-
tional Impact on Network Neighbors (MUFFINN) prediction scores are shown on left. Asterisk indicate samples from the same patient. Scale bar: 20 μm.
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Figure 2. Analysis of pleomorphic invasive lobular carcinoma–specific molecular alterations. Comparison of molecular alterations identified in (A) 
pleomorphic invasive lobular carcinoma (PILC) (n = 17) versus invasive ductal carcinoma (IDC) (n = 481) or (B) PILC (n = 17) versus ILC (n = 684). (C) Lol-
lipop plots depicting PILC somatic mutations in PIK3CA, CDH1, IGF1R, and INSR (R Package trackviewer, http://bioconductor.org/packages/release/
bioc/html/trackViewer.html). Protein-coding sequences and conserved domains derived from uniProt (25). (D) Network connection map of IRS2 and 
its direct neighbors, as predicted by MUtations For Functional Impact on Network Neighbors (MUFFINN). Gene-gene interactions are visualized by 
the CytoScape program (51). (E) Reactome pathway enrichment terms according to –log10 (P value) for PILC.
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The importance of  the IRS2 signaling pathway in 
PILC was further emphasized by the outcomes of  an 
analysis of  the somatic mutation data using the Reac-
tome database to identify biological pathways that are 
significantly enriched for mutations in PILC (Figure 2E) 
(14). The top hit for this analysis was “IRS-related events 
triggered by IGF1R,” and “Insulin receptor signaling cas-
cade” was also a significantly altered pathway. Additional 
pathways that were identified by the Reactome analysis 
and that also scored highly by MUFFINN analysis includ-
ed “PI3K/AKT signaling in cancer” and “PI3K events in 
ERBB2 signaling.” When downstream PI3K effectors are 
also considered, components of  the IR/IGF1R/IRS2/
PI3K signaling pathway were mutated in 15 of  17 (88%) 
PILC tumors. Of  note, PYGM, a gene involved in glyco-
gen metabolism, was previously identified as a frequently 
mutated gene in PILC (11). PYGM was not present in the TumorCare panel and therefore was not identi-
fied in our study. However, PGYM is regulated downstream of  IR/IGF1R/IRS2/PI3K signaling, and its 
mutation provides further evidence for the importance of  this pathway in the biology of  PILC (15).
IRS2 mutations enhance PILC invasion. The identification of  somatic mutations in IRS2 in 29% of  PILC 
samples is the first report of  recurrent IRS2 mutation in any subtype of  breast cancer to our knowledge. IRS2 
is an adaptor protein for the insulin and IGF-1 receptors, and it mediates their activation of  PI3K and MAPK 
signaling (16). IRS2 mutations are distributed throughout the protein (Figure 3A), as has been observed in 
other cancer types (17), and this likely reflects the multisite docking function of  this adaptor protein. With 
the exception of  the missense V1299I mutation, which is present in the COSMIC database, the remaining 
IRS2 mutations are novel missense mutations. We assessed the expression of  IRS2 in our data set of  PILC 
tumors by IHC staining. All PILC tumors were positive for IRS2 expression, which varied in expression level 
across the 17 tumors (Figure 3B). In a previous study, we identified three staining patterns for IRS2 in breast 
cancer. IRS2 was present at the cell membrane, diffusely cytoplasmic, or in a diffuse, cytoplasmic punctate 
pattern (18). We observed predominantly a punctate cytoplasmic staining pattern for IRS2 in PILC.
A critical issue that arises from our data is whether the IRS2 mutations we identified are function altering. 
Tumor cell functions that are regulated by IRS2 include glucose uptake, migration, and invasion (16). We 
initially investigated the effect of  IRS2 mutations on invasion because PILC tumors have a high incidence of  
lymphovascular invasion and lymph node metastasis (1). To investigate if  IRS2 mutations enhance invasive 
potential, WT-IRS2 and individual IRS2 mutants were initially expressed in either SUM-159:IRS1–/–,IRS2–/– 
human breast carcinoma cells (Figure 4A) or PyMT:Irs1–/–,Irs2–/– mouse mammary tumor cells (Figure 4G) 
(19). Both of  these cell lines are dependent upon IRS2 for invasion and their lack of  IRS2 expression permits 
analysis of  the IRS2 mutations without a background of  endogenous expression. Cells were embedded 
within a Matrigel/collagen I gel that mimics the tumor matrix microenvironment (20). Cells with limited 
invasion capacity or noninvasive cells grow as spherical colonies, and invasive cells form protrusions into the 
surrounding matrix. Invasive potential is monitored by the extent and distance of  cell branching from the 
colonies (Figure 4B). Cells expressing vector alone (pCDH or pcDNA) grew predominantly as spheroids, 
with minimal invasive branching, and expression of  WT-IRS2 increased invasion significantly (Figure 4, C 
and H). When compared with WT-IRS2, 3 of  the IRS2 mutants (S506G, A698T, and S1103L) stimulated a 
marked and significant increase in the percentage of  colonies with extensive invasive branching (Figure 4, 
C and H) and the distance that these branches invaded into the matrix (Figure 4, D and I). Representative 
images for each cell line are shown below the graphs.
Contrary to the IRS2-dependent increase in invasion, cell migration was not significantly enhanced by 
WT-IRS2 expression. Furthermore, no additional significant increases in migration were observed for any 
of  the IRS2 mutants (Figure 4E). Glucose uptake was significantly increased by WT-IRS2 expression; how-
ever, the IRS2 mutants did not further enhance uptake above WT-IRS2 levels (Figure 4F). Taken together, 
these results indicate a selective role for PILC IRS2 mutations in the regulation of  invasion.
We next validated the impact of  IRS2 mutations on invasion using a pleomorphic lobular carcinoma 
model. Mice with E-cadherin and p53 inactivation in the mammary epithelium develop invasive, metastatic 
Table 2. Top ranked genes by MUFFINN analysis
Rank Gene Mutation occurrence Score
1 PIK3CA 9 0.993
2 CDH1 10 0.989
3 IRS2 5 0.982
4 IGF1R 3 0.981
5 PIK3R1 2 0.947
6 SYNE1 7 0.947
7 HER2 3 0.906
8 INSR 3 0.898
9 KMT2D 5 0.89
10 PIK3R2 3 0.887
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tumors that phenocopy human PILC in both primary tumor histology and metastatic dissemination patterns 
(21). The KEP 1.11 murine PILC cell line derived from these tumors expresses endogenous Irs2 (Figure 
5A), and the invasive potential of  these cells is significantly reduced upon shRNA-mediated suppression of  
Irs2 expression (Figure 5B). This Irs2-mediated invasion is dependent upon upstream receptor activation, as 
the IR/IGF1R small-molecule inhibitor BMS-754807 blocked invasive branching without effecting colony 
number (Figure 5, C and D). WT-IRS2 and the IRS2 mutants were expressed in these cells, and the cells 
were assayed for their ability to invade (Figure 5E). A 2-fold increase in the extent of  invasive branching 
was observed upon expression of  exogenous WT-IRS2 (Figure 5F). Moreover, the 3 IRS2 mutants (S506G, 
A698T, and S1103L) that enhanced invasion in SUM-159 and PyMT cells stimulated a significant increase 
in the percentage of  colonies with extensive invasive branching (Figure 5F) and an increase in the distance 
these branches invaded into the matrix (Figure 5G) when compared with WT-IRS2. Neither migration nor 
glucose uptake were altered by expression of  the IRS2 mutants in the PILC cells (Figure 5, H and I), substan-
tiating the selective role of  these mutations in regulating invasion.
Discussion
We have characterized molecular alterations in PILC that provide insight into the aggressive behavior of  
this lobular breast cancer variant. Targeted sequencing analysis identified genes that are recurrently mutat-
ed in PILC and revealed that PILC is more similar to CILC than to IDC. Specifically, the frequency of  
molecular alterations in genes that have been reported to discriminate between lobular and ductal carcino-
ma, including TP53, MYC, GATA3, FOXA1, CDH1, and TBX3, was more similar to the frequency reported 
for ILC than that for IDC. Recurrent molecular alterations were also identified that distinguish PILC from 
CILC. Most notably, IRS2, which encodes the IRS2 adaptor protein that mediates signaling downstream 
Figure 3. Recurrent IRS2 mutations in pleomorphic invasive lobular carcinoma. (A) Lollipop plot of somatic mutations in IRS2. (B) Representative imag-
es of insulin receptor substrate 2 (IRS2) staining in pleomorphic invasive lobular carcinoma tumors. Scale bar: 20 μm.
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Figure 4. IRS2 mutations linked to invasion. (A) Immunoblots of cell extracts from SUM-159 parental cells and SUM-159:IRS1–/–,IRS2–/– cells stably 
expressing empty vector (pCDH), wild-type (WT) human insulin receptor substrate 2 (IRS2), or the IRS2 mutants identified in pleomorphic invasive 
lobular carcinoma (PILC). (B) Representative images used to score invasive colonies grown in Matrigel/collagen I gels. Cells grown in a Matrigel/
collagen I gel were scored for (C) the extent of invasion (mean ± SD, n = 20 wells from 5 independent experiments) or (D) the distance of invasive 
branching (mean ± SD, n = 50 colonies from 1 of 3 representative experiments). Representative images for each cell line are shown. (E) Cell migra-
tion assay using Transwell culture chambers (mean ± SD of 4 independent experiments). (F) Glucose uptake assay (mean ± SD of 4 independent 
experiments). (G) Immunoblots of cell extracts from PyMT:Irs1–/–,Irs2–/– cells stably expressing empty vector (pcDNA), wild-type human IRS2 (WT), 
or the IRS2 mutants identified in PILC. Cells grown in a Matrigel/collagen I gel were scored for (H) the extent of invasion (mean ± SD, n = 12 wells 
from 5 independent experiments) or (I) the distance of invasive branching (mean ± SD, n = 50 colonies from 1 of 3 representative experiments). Rep-
resentative images for each cell line are shown. Student’s t test was performed between vector (pCDH or pcDNA) and WT-IRS2, and 1-way ANOVA 
with Bonferroni post hoc testing was performed between WT-IRS2 and IRS2 mutants. *P < 0.05, relative to pCDH; ***P < 0.001, relative to pcDNA; 
#P < 0.05, ##P < 0.01, ###P < 0.001, relative to WT-IRS2. Scale bar: 20 μm.
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of  the insulin and IGF-1 receptors, is recurrently mutated in PILC. Pathway analysis revealed an important 
role for the IR/IGFIR/IRS2 signaling pathway in PILC. We validated this analysis by demonstrating that 
the IRS2 mutations identified in PILC enhance invasion, supporting a contribution of  this signaling adap-
tor to the aggressive behavior of  PILC.
Figure 5. IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma cells. (A) Immunoblots of cell extracts from KEP 1.11 murine 
pleomorphic invasive lobular carcinoma (PILC) cells stably expressing shGFP and 2 independent shRNA targeting Irs2 (shIrs2-1 and shIrs2-2). (B) Cells 
grown in a Matrigel/collagen I gel were scored for the distance of invasive branching (mean ± SD, n = 50 colonies from 1 of 2 representative experi-
ments). (C) KEP 1.11 cells expressing shGFP were serum starved and pretreated with DMSO or BMS-754807 at the concentrations indicated for 4 hours 
and stimulated with insulin-like growth factor-1 (IGF-1; 50 ng/ml) for 30 minutes. Cell extracts containing equivalent amounts of protein were immu-
noblotted with antibodies specific for insulin receptor substrate 2 (IRS2), pIGF1R (Y1135/1136)/pIR (T1150/1151), IGF1R, pAkt (S473), Akt, or Tubulin. 
(D) Cells grown in a Matrigel/collagen I gel were treated with DMSO or BMS-754807 (BMS, 100 nM) on day 3 and scored for the distance of invasive 
branching on day 7 (mean ± SD, n = 50 colonies from a representative experiment). (E) Immunoblots of cell extracts from KEP 1.11 cells stably express-
ing empty vector (pCDH), wild-type human IRS2 (WT), or the IRS2 mutants identified in PILC. Cells grown in a Matrigel/collagen I gel were scored for 
(F) the extent of invasion (mean ± SD of 3 independent experiments) or (G) the distance of invasive branching (mean ± SD, n = 50 colonies from 1 of 
3 representative experiments). Representative images for each cell line are shown. (H) Cell migration assay using Transwell culture chambers (mean 
± SD of 3 independent experiments). (I) Glucose uptake assay (mean ± SD of 4 independent experiments). Student’s t test was performed between 
pCDH and WT-IRS2, and 1-way ANOVA with Bonferroni post hoc testing was performed for all other comparisons. *P < 0.05, ***P < 0.001, relative to 
pLKO.1 or pCDH control; #P < 0.05, ##P < 0.01, ###P < 0.001, relative to WT-IRS2. Scale bar: 20 μm.
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IRS2 mutations have not been detected previously in breast cancer. However, somatic molecular alter-
ations of  IRS2 have been reported for other cancer types (22–28). Specifically, amplification of  IRS2 was 
first demonstrated in a study of  colorectal cancer (CRC) that investigated molecular alterations in the PI3K 
signaling pathway, and this amplification was shown in a later study to be mutually exclusive, with both 
mutations in PIK3CA and IGF2 overexpression (22, 25). IRS2 copy number gains were also reported in an 
analysis of  3,131 cancers across 26 histological cancer types (24) and in small cell lung cancer (28). In more 
recent genome sequencing studies, IRS2 somatic mutations were identified in CRC as well, although the 
consequences of  these alterations on tumor cell function were not directly investigated (26). Importantly, 
we identified a selective gain-of-function role for the PILC mutations in the promotion of  invasion.
We have previously demonstrated that metastasis is significantly impaired in mouse mammary tumor 
models in the absence of  Irs2 and enhanced in tumor cells that have increased Irs2 expression and activa-
tion (29, 30). Our current data reveal that the mutations found in PILC selectively enhance invasion and 
do not increase migration or glucose uptake. The ability of  these mutations to enhance tumor cell invasion 
highlights a mechanism that could contribute to the high incidence of  both regional and distant metastasis 
associated with PILC. An important question is how do the PILC mutations facilitate the ability of  IRS2 
to regulate invasion? The IRS adaptor proteins are recruited through N-terminal PH and PTB domains 
to activated insulin and IGF-1 receptors where they are phosphorylated by the intrinsic receptor tyrosine 
kinases to generate SH2-binding sites that mediate recruitment of  signaling effectors, in particular PI3K 
(31). The mutations identified in PILC are spread throughout the protein and do not occur in any of  the 
canonical SH2-binding motifs or the PH and PTB domains. Although the mutations could effect phosphor-
ylation or PI3K recruitment through indirect structural alterations, we did not detect significant differences 
in the kinetics or level of  tyrosine phosphorylation or recruitment of  PI3K between WT-IRS2 or any of  the 
IRS2 mutants (data not shown). These results suggest that the mechanism by which invasion is enhanced 
is likely independent of  this canonical IRS signaling pathway. The fact that IRS1 and IRS2 both activate 
PI3K but only IRS2 promotes invasion, and that 4 of  5 IRS2 mutations overlap with PIK3CA mutations 
in PILC tumors, also supports an alternative mechanism of  action. A reasonable hypothesis to be tested 
going forward is that the mutations that facilitate invasion enhance the interaction of  IRS2 with novel effec-
tor proteins. A better understanding of  IRS2 structure will be required to model the S506G, A698T, and 
S1103L mutations to predict how they positively alter IRS2 function to facilitate invasion.
Our identification of  genes and pathways that underlie the unique biology of  PILC has implications 
for the clinical management of  these highly invasive and metastatic tumors. Our data confirm that HER2 
is frequently mutated in PILC and support previous suggestions that PILC tumors that do not have HER2 
amplification should undergo sequencing to identify patients who would be responsive to HER2-target-
ed therapies (32). Previous trials of  drugs that target IR or IGF1R signaling have led to disappointing 
results for many different cancers, including breast cancer, and better biomarkers for selecting patients who 
would be responsive to these agents are needed (33, 34). IRS2 copy number gains were previously shown 
to enhance the sensitivity of  CRC cells to IR/IGF1R inhibition (35). Moreover, high IGF1R activity, as 
defined by an IGF-1 gene expression signature, correlates with sensitivity of  triple-negative breast cancer 
cells to BMS-754807 (36). Given our finding that targeting the IR/IGF1R pathway inhibits PILC invasion, 
the mutational status of  IRS2 may be exploited to identify PILC patients who are more likely to benefit 
from drugs that target this pathway to inhibit PILC progression and improve patient outcomes.
Methods
Targeted exome sequencing and analysis. Patient-matched tumor and normal specimens used in this study were 
obtained from the University of  Massachusetts Medical School Pathology archives. H&E-stained paraf-
fin tissue sections were reviewed by a board-certified breast pathologist to confirm a diagnosis of  PILC. 
Samples containing >60% tumor content were selected for the study, and tissue from 9 adjacent slides was 
macrodissected for analysis. Normal tissue from each subject was also macrodissected.
DNA extraction and targeted exome sequencing were performed by the Beijing Genomics Institute 
using their TumorCare panel. Qualified genomic DNA samples were randomly fragmented by Covaris, 
with a fragment size of  between 200 to 300 bp. Adapters were then ligated to both ends of  the resulting frag-
ments, and purified fragments with insert sizes of  approximately 250 bp were selected. The extracted DNA 
was then amplified by ligation-mediated PCR, purified, and hybridized to Roche NimbleGen SeqCap EZ 
Exome probes (Roche). The captured libraries of  each exome were sequenced on an Illumina Hiseq2000 
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system (Illumina). Raw image files were processed by Illumina CASAVA 1.7 software for base calling 
with default parameters, and the sequences of  each library were generated as 100-bp paired-end reads. 
The quality of  the reads was evaluated with fastqc (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/) and the Genome Analysis Toolkit (GATK) (version 3.5) was used for the variant calling according 
to GATK best practices (37).
Sequencing reads were aligned to the human reference genome, NCBI build 37 (hg19), using the fast 
and accurate short-read Burrows-Wheeler alignment algorithm (38). The mapping reads provided >99.5% 
coverage over the targeted exons at an average depth of  824× coverage (range 382× coverage to 1,390× 
coverage) (Figure 1F). The alignment results were combined into a single BAM format file for each sample, 
and duplicates were marked using the MarkDuplicates module in the Picard tool (http://broadinstitute.
github.io/picard/). Reads marked as duplicates were removed from downstream analysis. Local realign-
ment and quality score recalibration were performed using the GATK with default parameters.
Somatic single nucleotide variants (SNVs) and small insertion/deletions (Indels) were called using the 
MuTect2 algorithm in GATK3.5 with default parameters. The functional annotation of  the called variants 
was performed using ANNOVAR (39, 40). Exome CNVs were statistically processed by exome sequenc-
ing–based CNV and loss of  heterozygosity detection (ExomeCNV) (41) with the sample admixture rate 
(normal cell contamination rate) set at 0.3 to reduce the number of  false positive calls. After calculating 
depth-of-coverage and B allele frequencies using the DepthOfCoverage module in GATK3.5, CNVs were 
called at each exon, which were then combined into segments using circular binary segmentation (42). 
CNVs with a log2 copy ratio ≥1 or ≤–1 were defined as copy number gains (amplification) or losses (dele-
tion), respectively. All candidate SNVs, indels, and CNVs were further manually reviewed using the Inte-
grative Genomics Viewer (43). The confident variant results were then annotated using the Bioconductor 
package ChIPpeakAnno (version 3.8.2) (44). Genes predicted to have deleterious mutations by Condel 
(45), damaging mutations by FATHMM (46) or LRT (47), or scaled CADD (48) value ≥10 were included 
in the filtered data set of  somatic mutations (Supplemental Table 2).
The filtered data set of  genes containing PILC molecular alterations was analyzed by MUFFINN to 
identify functionally relevant genes for PILC (13). Results of  this analysis are reported as probability scores 
between 0 and 1. Pathway analysis of  the PILC data set was performed using the Reactome database 
(http://www.reactome.org/) (14).
Cell lines. SUM-159 cells were a gift from Arthur Mercurio (University of  Massachusetts Medical 
School) and were grown in F12 media (Gibco) containing 5% FBS (MilliporeSigma), 5 μg/ml insulin 
(MilliporeSigma), and 1 μg/ml hydrocortisone (MilliporeSigma). Mammary tumor cells were isolat-
ed from female FVB MMTV-PyMT:Irs1fl/fl,Irs2fl/fl mice, and PyMT:Irs1–/–,Irs2–/– cells were generated by 
infection with adenoviral Cre recombinase as described previously (19). PyMT mouse mammary tumor 
cells were grown in low-glucose (1 g/l) DMEM (Corning) containing 10% FBS. KEP 1.11 murine PILC 
cells were a gift from Jos Jonkers (Netherlands Cancer Institute, Amsterdam, the Netherlands) and 
were grown in DMEM/F12 media containing 10% FBS, Penicillin-Streptomycin (100 U/ml) (Gibco), 
5 ng/ml insulin, 5 ng/ml epidermal growth factor (MilliporeSigma), and 5 ng/ml cholera toxin (Milli-
poreSigma) (21). All cells tested negative for mycoplasma using the Morwell MD Biosciences EZ PCR 
Mycoplasma Test Kit (catalog 409010).
IRS1/IRS2 double-null SUM-159 cells were generated by CRISPR/Cas9-mediated gene editing. 
gRNAs were designed using MIT CRISPR DESIGN (http://crispr.mit.edu/) to target an early 5′ exon 
region for either IRS1 (sequence of  gRNA: GCATGCTCTTGGGTTTGCGCAGG) or IRS2 (sequence 
of  gRNA: AACCACAGCGTGCGCAAGTGCGG). All gRNAs were subcloned into the pSpCas9(B-
B)-2A-GFP plasmid (Addgene, 48138) (49). Cells were transfected with the CRISPR plasmid containing 
the IRS1-gRNA using Lipofectamine 2000 (Invitrogen) and sorted by flow cytometry for the GFPhi pop-
ulation to obtain IRS1–/– cells. IRS1–/– cells were transfected with the CRISPR plasmid containing the 
IRS2-specific gRNA and sorted for GFP high cells to generate SUM-159:IRS1–/–,IRS2–/– cells. Wild-type 
IRS2 and the IRS2 mutants were subcloned into the pCDH-CMV-MCS-EF1-puro lentiviral vector (System 
Bioscience), and SUM-159:IRS1–/–,IRS2–/– cells were infected and selected in 2 μg/ml puromycin (Gold 
Biotechnology). PyMT:Irs1–/–,Irs2–/– mouse mammary tumor cells were transfected with human WT-IRS2 
and the IRS2 mutants in pcDNA3.1 and selected in 500 μg/ml G418 (Gibco). Lentiviral vectors (pLKO.1) 
containing small hairpin RNAs (shRNAs) targeting the open reading frame region of  Irs2 were obtained 
from Open Biosystems (TRCN0000055108 and TRCN0000055110).
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For IGF1R/IR inhibition, cells were serum starved and pretreated with BMS-754807 for 4 hours before 
stimulation for 30 minutes with human recombinant IGF-1 (50 ng/ml) (R&D Systems). Cells were solu-
bilized at 4oC in a 20 mM Tris, pH 7.4 buffer containing 1% nonidet P-40, 150 mM sodium chloride, 10% 
glycerol, 10 mM sodium fluoride, 1 mM sodium orthovanadate, and protease inhibitors (Roche). The dual 
IGF1R/IR inhibitor BMS-754807 was obtained from Selleckchem (catalog S1124).
Immunoblotting. Cell extracts containing equivalent amounts of  total protein were resolved by SDS-
PAGE and transferred to nitrocellulose membranes. The membranes were blocked for 1 hour with a 
50 mM Tris buffer, pH 7.5, containing 0.15 M NaCl, 0.05% Tween 20, and 5% (wt/vol) dry milk and 
incubated overnight at 4oC in the same blocking buffer containing primary antibodies. After washing, 
the membranes were incubated for 1 hour in blocking buffer containing peroxidase-conjugated second-
ary antibodies. Proteins were detected by enhanced chemiluminescence (Bio-Rad). Antibodies used for 
immunoblotting include IRS2 (Cell Signaling, 4502), pIGF1R(Y1135/1136)/pIR(T1150/1151) (Cell 
Signaling, 3024), IGF1R (Cell Signaling, 3027), pAkt (S473) (Cell Signaling, 9271), Akt (Cell Signal-
ing, 9272), Tubulin (MilliporeSigma, T5168), and peroxidase-conjugated goat anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories Inc., 111-035-144) or goat anti-mouse IgG (Jackson ImmunoResearch 
Laboratories Inc., 711-035-151).
Immunohistochemistry. Formalin-fixed, paraffin-embedded tissue sections (5 μM) were deparaffin-
ized and rehydrated, and antigen retrieval was carried out in 10 mM sodium citrate, pH 6.0, with 
heating in a steamer for 60 minutes. Tissue sections were blocked with a Avidin/Biotin Blocking 
Kit (Vector Laboratories) followed by 1× Casein Solution (Vector Laboratories, SP-5020) for 1 hour. 
Sections were stained with rabbit monoclonal IRS2 (1:700; Abcam, EP976Y) and counterstained with 
hematoxylin. Stained tumor sections were viewed on an Olympus BX41 light microscope (Olympus). 
Photomicrographs were obtained using an Evolution MPColor camera (Media Cybernetics).
Invasion assay. 2,500 cells were suspended in a mixture of  Matrigel (2 mg/ml) and collagen I (1 mg/
ml) and plated over a base gel layer of  the same matrix composition in 8-well chamber glass slides. The 
gels were overlaid with complete serum-containing medium, which was changed every 2 days for 7–8 days. 
DMSO or BMS-754807 (100 nM) was added to the wells on day 3. Colonies were imaged and scored for 
the extent of  cell invasion/branching using a Nikon Diaphot 300 microscope. Cell invasion was catego-
rized into 4 levels, none (level 1), low (level 2), medium (level 3), and high (level 4), depending upon the 
extent of  tumor cell dissemination from the colonies into the surrounding matrix (Figure 4B). Invasion was 
scored as the percentage of  highly invasive colonies (level 3 and 4) in each well. The distance of  invasion 
was determined by measuring from the center of  the colonies to the outer tip of  the invasive branches. 
Relative invasion was measured as the fold change in invasion (percentage or distance) compared with 
cells expressing WT-IRS2. Matrigel and collagen I were obtained from Corning Discovery Labware Inc. 
(354230 and 354236, respectively).
Migration assay. Migration assays were performed using Transwell chambers (Corning) as described pre-
viously (50). Briefly, cells (1 × 105) were resuspended in F12 medium containing 0.5% FBS and seeded in 
triplicate in the upper wells of  the Transwell chambers. F12 medium containing 0.5% FBS and 40 μg/ml 
collagen I was added to the lower wells. After 2.5 hours, cells that migrated to the lower surface of  the mem-
brane were fixed with ice-cold 100% methanol, and the fixed membranes were mounted on glass slides using 
Vectashield mounting medium with DAPI (Vector Laboratories). Migration was quantified by counting the 
number of  stained nuclei and normalized to that of  vector control cells to calculate relative migration.
Glucose uptake assay. Cells were grown in 12-well plates to near confluence, washed with PBS, and then 
incubated in 0.1% BSA/DMEM (1 g/l glucose) for 24 hours. Glucose levels in the media were measured 
using a glucose (GO) Assay kit (MilliporeSigma, GAGO20) according to the manufacturer’s instructions. 
Glucose uptake was expressed as a rate measurement (mM/mg/h) normalized to total protein in each well.
Statistics. Statistical analysis between vector control (pCDH or pcDNA) and IRS2-WT was per-
formed using a 2-tailed unpaired Student’s t test. Statistical analysis between IRS2-WT and the IRS2 
mutants was performed using 1-way ANOVA followed by Bonferroni’s multiple comparisons testing. 
All statistical analysis was performed using Prism7, Graphpad. A 2-sided P value of  less than 0.05 was 
considered to indicate statistical significance.
Study approval. The study was approved and performed in accordance with standards established by 
the University of  Massachusetts Medical School Institutional Review Board, consistent with applicable 
national and state laws and regulations. Tissue was acquired through a waiver of  consent for retrospective 
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data collection. Primary sequencing data have been deposited in the European Genome-phenome Archive 
under controlled access (accession EGAD00001003995).
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